Loading...
Loading...
RMTI| Name | Value |
|---|---|
| Revenues | 19.7M |
| Cost of Revenue | 17.1M |
| Gross Profit | 2.6M |
| Operating Expense | 4.0M |
| Operating I/L | -1.4M |
| Other Income/Expense | -0.3M |
| Interest Income | 0.1M |
| Pretax | -1.8M |
| Income Tax Expense | 0.7M |
| Net Income/Loss | -2.5M |
Rockwell Medical, Inc. is a biopharmaceutical company specializing in therapies and products for end-stage renal disease and chronic kidney disease. Its flagship products, Triferic Dialysate and Triferic AVNU, provide iron therapy for dialysis patients without increasing iron stores. The company also manufactures and distributes hemodialysis concentrates, ancillary products, and supplies used by hemodialysis providers. Additionally, it is developing therapeutic product candidates for acute heart failure treatment and home infusion therapy. Rockwell Medical's revenue is generated through the sale, delivery, and distribution of its dialysis concentrates, ancillary products, and potential future therapeutic products.
